| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| April McClain Delaney MD06 | 5 | 6 | −$8.0K | Sold Apr 8, 26 |
| Rob Bresnahan PA08 | 1 | 1 | +$0 | Sold Apr 8, 25 |
| Julie Johnson TX32 | 1 | −$8.0K | Sold Apr 1, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Apr 8, 26 | April McClain Delaney MD06 | Child | Sell | $1,001 - $15,000 | May 6, 26 (28d) | |
| Mar 26, 26 | April McClain Delaney MD06 | Child | Sell (part) | $1,001 - $15,000 | Apr 6, 26 (11d) | |
| Feb 24, 26 | April McClain Delaney MD06 | Child | Sell (part) | $1,001 - $15,000 | Mar 10, 26 (14d) | |
| Jan 28, 26 | April McClain Delaney MD06 | Child | Sell (part) | $1,001 - $15,000 | Feb 2, 26 (5d) | |
| Dec 5, 25 | April McClain Delaney MD06 | Child | Buy | $1,001 - $15,000 | Jan 5, 26 (31d) | |
| Dec 2, 25 | April McClain Delaney MD06 | Child | Buy | $1,001 - $15,000 | Jan 5, 26 (34d) | |
| Oct 22, 25 | April McClain Delaney MD06 | Child | Buy | $1,001 - $15,000 | Nov 4, 25 (13d) | |
| Aug 1, 25 | April McClain Delaney MD06 | Child | Sell (part) | $1,001 - $15,000 | Sep 2, 25 (32d) | |
| May 26, 25 | April McClain Delaney MD06 | Child | Sell (part) | $1,001 - $15,000 | Jul 2, 25 (37d) | |
| Apr 29, 25 | April McClain Delaney MD06 | Child | Buy | $1,001 - $15,000 | May 2, 25 (3d) | |
| Apr 9, 25 | April McClain Delaney MD06 | Child | Buy | $1,001 - $15,000 | May 2, 25 (23d) | |
| Apr 8, 25 | Rob Bresnahan PA08 | Self | Sell | $1,001 - $15,000 | May 8, 25 (30d) | |
| Apr 1, 25 | Julie Johnson TX32 | Joint | Sell | $1,001 - $15,000 | May 14, 25 (43d) | |
| Feb 25, 25 | Rob Bresnahan PA08 | Self | Buy | $1,001 - $15,000 | Mar 27, 25 (30d) |
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 27, 2026 | Higgins John LDirector | Conversion of Exercise of derivative security at price 25.30 per share. | 15.9K | $403.28K |
| Aug 13, 2026 | Crouse Steven C.Officer | — | 5.4K | — |
| Aug 13, 2026 | Hippel JamesChief Financial Officer | — | 9.8K | — |
| Aug 13, 2026 | Kelderman KimChief Executive Officer | — | 21.5K | — |
| Aug 13, 2026 | Geist WilliamOfficer | — | 6.4K | — |
| Aug 13, 2026 | Bohnen ShaneGeneral Counsel | — | 4.3K | — |
| Aug 13, 2026 | Herr Amy E.Director | — | 589 | — |
| Jul 28, 2026 | Hippel JamesChief Financial Officer | Conversion of Exercise of derivative security at price 47.60 per share. | 62.1K | $2.95M |
| Jul 27, 2026 | Kelderman KimChief Executive Officer | Conversion of Exercise of derivative security at price 47.60 per share. | 35K | $1.67M |
| Jul 22, 2026 | Bohnen ShaneGeneral Counsel | Conversion of Exercise of derivative security at price 47.60 per share. | 448 | $21.32K |
| Jun 1, 2026 | Crouse Steven C.Officer | — | 600 | — |
| May 7, 2026 | Herr Amy E.Director | Sale at price 48.28 per share. | 6.6K | $320.39K |
| May 7, 2026 | Herr Amy E.Director | Conversion of Exercise of derivative security at price 47.60 per share. | 6.6K | $315.87K |
| May 4, 2026 | Hippel JamesChief Financial Officer | Conversion of Exercise of derivative security at price 47.60 per share. | 62K | $2.95M |
| May 4, 2026 | Kelderman KimChief Executive Officer | Conversion of Exercise of derivative security at price 47.60 per share. | 26.7K | $1.27M |
| May 4, 2026 | Bohnen ShaneGeneral Counsel | Conversion of Exercise of derivative security at price 47.60 per share. | 8.4K | $399.84K |
| Apr 30, 2026 | Crouse Steven C.Officer | — | 794 | — |
| Apr 21, 2026 | Hippel JamesChief Financial Officer | — | 62K | — |
| Apr 21, 2026 | Kelderman KimChief Executive Officer | — | 11.3K | — |
| Apr 13, 2026 | Kelderman KimChief Executive Officer | Conversion of Exercise of derivative security at price 47.60 per share. | 36.5K | $1.74M |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 9.0 | -7.9 | -11.4 | 5.9 | -6.6 | 36.7 | 2.0 | 0.3 | 0.2 | 0.1 | +23.4% | ||
| 2025 | 2.1 | -16.0 | -5.1 | -14.1 | -3.9 | 6.3 | 6.4 | -0.2 | 1.8 | 12.5 | 3.1 | -8.8 | −18.4% |
| 2024 | -8.9 | 4.6 | -4.3 | -10.2 | 22.1 | -7.2 | 13.9 | -9.3 | 8.0 | -7.7 | 2.2 | -4.4 | −6.6% |
| 2023 | -3.9 | -8.8 | 2.1 | 7.7 | 2.4 | -0.2 | 2.2 | -6.0 | -13.2 | -19.7 | 15.1 | 22.7 | −6.9% |
| 2022 | -27.2 | 11.4 | 3.2 | -12.3 | -2.6 | -6.2 | 11.1 | -13.9 | -14.4 | 4.3 | 14.8 | -2.5 | −35.9% |
| 2021 | 2.3 | 11.3 | 5.6 | 11.9 | -3.2 | 8.8 | 7.1 | 3.5 | -2.9 | 8.1 | -9.9 | 9.6 | +62.9% |
| 2020 | -4.3 | -10.0 | 0.4 | 18.7 | 17.7 | -0.3 | 4.2 | -7.2 | -3.0 | 1.9 | 20.2 | 4.7 | +44.7% |
| 2019 | 20.6 | 11.1 | 2.4 | 3.0 | -3.2 | 5.3 | 0.8 | -8.8 | 2.1 | 6.4 | 4.8 | 0.6 | +51.7% |
| 2018 | 8.3 | 0.7 | 6.9 | -0.1 | -0.4 | -1.6 | 8.6 | 19.6 | 6.2 | -17.8 | -3.8 | -10.3 | +11.7% |
| 2017 | -1.1 | 4.5 | -4.4 | 5.3 | 4.7 | 4.8 | -1.4 | 6.8 | -2.3 | 8.4 | 2.8 | -3.9 | +26.0% |
| 2016 | -8.1 | 3.8 | 10.1 | -1.4 | 17.9 | 2.6 | -0.3 | -6.3 | 3.9 | -5.0 | 1.3 | -2.4 | +14.3% |
| 2015 | 0.7 | 4.8 | 2.8 | -4.3 | 5.5 | -2.7 | 11.1 | -13.6 | -2.1 | -4.6 | 3.4 | -1.3 | −2.6% |
| 2014 | -4.0 | -2.2 | -3.9 | 4.6 | -1.7 | 5.4 | 0.8 | 2.4 | -2.1 | -2.7 | 0.6 | 0.9 | −2.4% |
| 2013 | 4.9 | -5.1 | -0.2 | -5.5 | 3.7 | 3.9 | 6.7 | 5.1 | 3.3 | 9.2 | -2.1 | 10.7 | +38.5% |
| 2012 | -0.0 | 4.9 | -2.1 | -4.5 | 1.4 | 9.3 | -6.9 | -0.7 | 4.9 | -6.4 | 5.3 | -3.6 | +0.1% |
| 2011 | 5.0 | 4.0 | -0.1 | 8.5 | 4.9 | 2.3 | -9.1 | -4.4 | -6.2 | 1.2 | -1.9 | 1.1 | +3.9% |
| 2010 | -4.3 | -2.6 | -0.5 | 4.2 | -8.6 | -5.1 | 1.7 | -1.1 | 6.9 | -1.3 | -1.4 | 9.3 | −4.2% |
| 2009 | -7.1 | -18.5 | 12.0 | 4.6 | 5.3 | 5.9 | 0.0 | -3.4 | 1.4 | -0.1 | 8.6 | 1.0 | +6.3% |
| 2008 | -1.6 | 5.2 | -1.5 | 7.7 | 8.2 | -1.4 | 2.8 | -3.0 | -6.5 | -4.3 | -10.2 | 4.0 | −2.3% |
| 2007 | 4.7 | -3.0 | 1.4 | 3.3 | 1.2 | -4.2 | -1.7 | 12.0 | 0.1 | 3.4 | -0.1 | 1.4 | +19.1% |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Buy / hold / sell counts